Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2018

View Archived Issues

miRNA551b found as therapeutic target for AML

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Scripps Research Institute presents mu-opioid receptor ligand SR-17018

CSIC Zika virus vaccine shows promise in mouse infection models

Ionis begins phase I/II study of ION-TTR-LRx in healthy subjects and patients with hATTR

New tumor organoid includes microenvironment

Responses seen with blinatumomab monotherapy in relapsed/refractory B-cell non-Hodgkin's lymphoma

Rivaroxaban thromboprophylaxis effective only during treatment period in cancer patients

Quinazoline can serve as a novel core structure in the design of potent BRD4 inhibitors

ASLAN Pharmaceuticals presents phase II data for ASLAN-003 in AML patients

Geranylgeranyl diphosphate synthase inhibitors RAM-2061, RAM-2093 show promise for multiple myeloma

Aimmune Therapeutics submits IND application for AR-201 as treatment of egg allergy

Combination approach revs up beta cell production

Platform could prove broad strategy against emerging viruses

MUC17 and PCNX1 as novel biomarkers of chemotherapy response in breast cancer

Elzonris receives FDA approval for the treatment of blastic plasmacytoid dendritic cell neoplasm

Novartis receives approval in the E.U. for expanded indication for Kisqali

Suglat Tablets approved for additional indication of type 1 diabetes mellitus in Japan

FDA approves Inbrija

FDA grants early approval for Ultomiris for the treatment of adults with PNH

Merck KGaA and Pfizer terminate JAVELIN Ovarian 100 study of avelumab

Phase II TRAXAR study does not meet primary endpoint

Life Science Institute initiates exploratory clinical trial of CL-2020 in epidermolysis bullosa

Novartis reports compounds for treatment of parasitic diseases

Esteve Pharmaceuticals patent reports agents for the treatment of pain

Hemlibra subcutaneous injection approved in Japan for hemophilia A without inhibitors

Chugai receives approval in Japan for Tecentriq for additional dosing in NSCLC

FDA approves IND for anti-GM-CSF monoclonal antibody TJM2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...